The Latest Breaking News from Johnson & Johnson (

Amid rising healthcare demand globally, advancements in precision medicine, and the booming e-pharmacy market, the pharmaceutical industry is expected to witness significant long-term growth. Hence, fundamentally sound pharma stocks Dr. Reddy’s Laboratories (RDY), Ipsen (IPSEY), and Johnson & Johnson (JNJ), which boast low beta values and attractive valuation metrics, might…

Dividend Kings are companies with a long history of paying and increasing shareholder dividends, which signals strong financial health for investors looking to build a steady stream of passive income.

The market rally continued amid near-perfect economic data. ASML and Netflix were earning winners. Tesla and Intel dived on guidance.

Johnson & Johnson beat fourth-quarter expectations Tuesday, helped by strength from its medtech segment. But JNJ stock toppled.

Eight Dow Jones stock report earnings this week. Several, including Verizon and 3M, are in buy zones or near buy points.

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However, with the company’s fiscal fourth-quarter earnings on the horizon, could the stock be a wise portfolio addition? Keep reading to find out….

Georgia-Pacific, owned by Koch Industries, employ controversial legal tactic to circumvent paying millions to sickened workers

High yields aren't the only reason to buy shares of dividend-paying stocks. For investors seeking quality dividend stocks for passive income, here's a look at two companies with long track records of raising shareholder payouts.

Dr. Wanda Austin has joined Apple's board of directors, while former U.S. VP Al Gore has departed.